Literature DB >> 15665742

A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma.

Jan Gerard Maring1, Leonie Schouten, Ben Greijdanus, Elisabeth G E de Vries, Donald R A Uges.   

Abstract

The authors developed a simple and sensitive, fully validated HPLC-UV method for the determination of both 5-FU and its metabolite DHFU in small-volume plasma samples. The analytes were separated on a 4.6 x 250 mm ID Atlantis dC18 5-microm column with isocratic elution at room temperature. Chlorouracil was used as internal standard. The analytes were detected with an UV diode array detector. DHFU was detected at 205 nm, 5-FU at 266 nm, and chlorouracil at both wavelengths. The limits of quantification in plasma were 0.040 mug /mL for 5-FU and 0.075 microg/mL for DHFU. Linearity, accuracy, precision, recovery, dilution, freeze-thaw stability, and stability in the sample compartment were evaluated. The method appeared linear over a range from 0.04 to 15.90 microg/mL for 5-FU and from 0.075 to 3.84 microg/mL for DHFU. The method appeared very suitable for therapeutic drug monitoring and pharmacokinetic studies of 5-FU because of its simple extraction and small sample volume. Problems in earlier published methods with interfering peaks and variable retention times were overcome. The method appeared also to be suitable for detection of uracil and its metabolite dihydrouracil in plasma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665742     DOI: 10.1097/00007691-200502000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Authors:  Daniel Kozo; Matt W Ross; Justin Jarrah; Michael Barrett; Rebecca L Harney; Jodi B Courtney; Irina Baburina; Julianne L Holleran; Jan H Beumer; Godefridus J Peters; Richard J Honeywell; Salvatore J Salamone
Journal:  Ther Drug Monit       Date:  2017-06       Impact factor: 3.681

2.  Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

Authors:  André B P van Kuilenburg; Peter Häusler; Andreas Schalhorn; Michael W T Tanck; Johannes H Proost; Christoph Terborg; Detlev Behnke; Wolfgang Schwabe; Kati Jabschinsky; Jan Gerard Maring
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

3.  Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.

Authors:  Maurice C van Staveren; Andre B P van Kuilenburg; Henk-Jan Guchelaar; Judith Meijer; Cornelis J A Punt; Robert S de Jong; Hans Gelderblom; Jan Gerard Maring
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

4.  Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.

Authors:  Maurice C van Staveren; Barbara Theeuwes-Oonk; Henk Jan Guchelaar; André B P van Kuilenburg; Jan Gerard Maring
Journal:  Cancer Chemother Pharmacol       Date:  2011-05-18       Impact factor: 3.333

5.  Ultrasensitive and Specific Detection of Anticancer Drug 5-Fluorouracil in Blood Samples by a Surface-Enhanced Raman Scattering (SERS)-Based Lateral Flow Immunochromatographic Assay.

Authors:  Hanwen Liu; Ying Liu; Ting Zhou; Penghui Zhou; Jianguo Li; Anping Deng
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.